Thus, given the divergent expression of these various IL-2 receptors (IL-2Rs), IL-2 therapy has been an attractive therapeutic concept to promote either immunity (by triggering the intermediate-affinity dimeric IL-2R on effector immune cells to combat cancer), or immune suppression (by triggering the high-affinity trimeric IL-2R on Tregs in the context of autoimmunity and transplantation). The gene discussed is IL2; the disease is Autoimmunity.